 Although effective in and , bicalutamide is no longer indicated for the treatment of localized prostate cancer (LPC) due to negative findings in the Early Prostate Cancer (EPC) trial.Prior to the introduction of the newer enzalutamide in 2012, bicalutamide was considered to be the standard-of-care antiandrogen in the treatment of prostate cancer, and still remains widely used for this indication.Compared to earlier antiandrogens like the steroidal antiandrogen (SAA) cyproterone acetate (CPA) and the flutamide and nilutamide, bicalutamide shows an improved profile of effectiveness, tolerability, and safety, and for this reason has largely replaced them in the treatment of prostate cancer.